PharmaEssentia Corporation (LUX:261280523)
Luxembourg · Delayed Price · Currency is EUR · Price in USD 16.10
-0.10 (-0.62%)
At close: Nov 10, 2025
PharmaEssentia Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 13,815 | 9,735 | 5,106 | 2,882 | 656.51 | 557.26 | Upgrade | |
Revenue Growth (YoY) | 66.04% | 90.67% | 77.15% | 339.00% | 17.81% | 82.29% | Upgrade |
Cost of Revenue | 1,496 | 1,177 | 610.54 | 812.29 | 378.86 | 373.32 | Upgrade |
Gross Profit | 12,319 | 8,558 | 4,495 | 2,070 | 277.65 | 183.93 | Upgrade |
Selling, General & Admin | 5,183 | 4,234 | 4,184 | 2,672 | 1,827 | 977.41 | Upgrade |
Research & Development | 3,228 | 2,588 | 2,224 | 1,426 | 1,273 | 922.38 | Upgrade |
Operating Expenses | 8,411 | 6,822 | 6,408 | 4,098 | 3,100 | 1,900 | Upgrade |
Operating Income | 3,908 | 1,736 | -1,913 | -2,028 | -2,822 | -1,716 | Upgrade |
Interest Expense | -25.07 | -22.19 | -46.69 | -18.53 | -9.97 | -8.26 | Upgrade |
Interest & Investment Income | 721.81 | 924.06 | 585.13 | 40.44 | 4.63 | 7.49 | Upgrade |
Currency Exchange Gain (Loss) | -754.86 | 376.38 | 375.7 | 122.36 | -1.85 | 9.82 | Upgrade |
Other Non Operating Income (Expenses) | -24.56 | -18.74 | 12.33 | 42.15 | 4.09 | -264.94 | Upgrade |
EBT Excluding Unusual Items | 3,823 | 2,996 | -986.93 | -1,842 | -2,826 | -1,972 | Upgrade |
Gain (Loss) on Sale of Assets | -1.12 | -0.93 | - | -0.1 | -0.07 | 0.02 | Upgrade |
Other Unusual Items | - | - | - | - | 14.59 | 23.71 | Upgrade |
Pretax Income | 3,822 | 2,995 | -986.93 | -1,842 | -2,811 | -1,948 | Upgrade |
Income Tax Expense | -982.24 | 29.15 | -363.1 | -467.06 | - | 0.13 | Upgrade |
Net Income | 4,804 | 2,966 | -623.84 | -1,375 | -2,811 | -1,948 | Upgrade |
Net Income to Common | 4,804 | 2,966 | -623.84 | -1,375 | -2,811 | -1,948 | Upgrade |
Shares Outstanding (Basic) | 369 | 367 | 358 | 315 | 289 | 269 | Upgrade |
Shares Outstanding (Diluted) | 371 | 371 | 358 | 315 | 289 | 269 | Upgrade |
Shares Change (YoY) | 0.44% | 3.59% | 13.47% | 9.24% | 7.39% | 10.55% | Upgrade |
EPS (Basic) | 13.03 | 8.07 | -1.74 | -4.36 | -9.74 | -7.25 | Upgrade |
EPS (Diluted) | 12.95 | 8.00 | -1.74 | -4.36 | -9.74 | -7.25 | Upgrade |
Free Cash Flow | 3,025 | 1,685 | -1,996 | -1,818 | -2,532 | -1,536 | Upgrade |
Free Cash Flow Per Share | 8.15 | 4.54 | -5.58 | -5.76 | -8.77 | -5.71 | Upgrade |
Dividend Per Share | 0.990 | 0.990 | - | - | - | - | Upgrade |
Gross Margin | 89.17% | 87.91% | 88.04% | 71.82% | 42.29% | 33.01% | Upgrade |
Operating Margin | 28.29% | 17.83% | -37.48% | -70.37% | -429.91% | -307.91% | Upgrade |
Profit Margin | 34.78% | 30.46% | -12.22% | -47.70% | -428.17% | -349.60% | Upgrade |
Free Cash Flow Margin | 21.90% | 17.31% | -39.09% | -63.06% | -385.74% | -275.72% | Upgrade |
EBITDA | 4,031 | 1,847 | -1,824 | -1,912 | -2,703 | -1,621 | Upgrade |
EBITDA Margin | 29.18% | 18.97% | -35.73% | -66.34% | - | -290.92% | Upgrade |
D&A For EBITDA | 123.15 | 110.52 | 89.24 | 116.28 | 119.59 | 94.7 | Upgrade |
EBIT | 3,908 | 1,736 | -1,913 | -2,028 | -2,822 | -1,716 | Upgrade |
EBIT Margin | 28.29% | 17.83% | -37.48% | -70.37% | - | - | Upgrade |
Effective Tax Rate | - | 0.97% | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.